Important note: Information in this article was accurate in May 2008. The state of the art may have changed since the publication date.
Responses to atazanavir-containing HAART in treatment-naïve children in South Africa
HIV Treat Bull - 2008 May-June;9(5/6):19
Polly Clayden, HIV i-Base
A poster authored by Megan Palmer and coworkers from the United States and South Africa presented findings from PACTG 1020A. This is a phase I/II study of atazanavir (ATV) with or without ritonavir (r) with 2 NRTI (excluding tenofovir [TDF]) in HIV-positive treatment-naïve children aged 91 days to 21 years.
This poster showed data from treatment-naïve South African children participating in the dose-finding study, for age (<2 years, 2 to 13 years, >13 years) and formulation (powder vs capsule) groups.
Each group started with a dose of 310 mg/m2 of ATV, which was adjusted based on day 7 24-hour, intensive PK and week 4 safety data. Acceptable PK and safety dose criteria were: AUC ≥30 µg*hour/mL and C24 ≥60 ng/mL in 4 of 5 children; no AUC <15 µg*hour/mL; and median AUC for 5 children ≤60 µg*hour/mL and ≤1 of 5 children with ≥ grade 3 adverse events, none life-threatening.
Guided by these criteria, the investigators either enrolled an additional 5 children at the starting dose or the starting dose was adjusted. An optimal dose was based on ≥10 evaluable children with acceptable PK and safety results.
The study has enrolled 183 children to date of this evaluation; 62 from South Africa.
This report showed 48-week treatment outcomes for 57 South African children receiving unboosted (n=22) and boosted (n=35) ATV. Approximately half (29/57) of the children were girls.
At baseline, the children were a median of 6 years of age (91 days to 21 years); CD4 count, 411 cells/mm3 (24 to 2192); CD4%, 13% (1 to 35); log10 viral load, 5.0 (3.6 to 5); and mean height z-score, –2.09 (–4.56 to 0.73) and weight z-score, –1.98 (–5.80 to 0.91).
The investigators reported that 35/48 of the children (73%, 95%CI 58% to 85%) had viral load <400 copies/mL at 48 weeks, in an intent-to-treat analysis. Weight and height z-score improved significantly at the same time point; mean change in height z-score +0.27 (p=0.04) and mean change in weight z-score +0.79 (p<0.0001).
11 children discontinued ATV, of these, 5 were due to toxicity (hyperbilirubinemia, LFT increase, or QT interval changes), 1 due to death (unrelated, pneumonia), and 5 for other reasons (eg lost to follow-up, need for protocol disallowed medications).
The investigators noted that RTV boosting of the capsule significantly improved PK parameters of ATV. The dose of 310 mg/m2 for powder and 205 mg/m2 for capsule plus RTV passed protocol defined safety parameters.
They also found in this South African cohort children were severely malnourished at baseline and weight and height z-scores improved significantly.
Ref: Meyers T, Rutstein R, Samson P et al. Treatment responses to atazanavir-containing HAART in a drug-naïve paediatric population in South Africa. Conf Retroviruses Opportunistic Infect. 2008 Feb 3-6;15: Poster abstract 582.
2008-05-10
IB080905-16
©2008. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.